Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy
Objectives: Advanced Hodgkin’s lymphoma (HL) is a rare severe neoplasm, significantly limiting the ability of patients to do daily activities among other impacts of the cancer. Many adult patients present with advanced stage disease (stages III/IV). This analysis investigates the cost-effectiveness...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AboutScience Srl
2024-12-01
|
| Col·lecció: | Global & Regional Health Technology Assessment |
| Matèries: | |
| Accés en línia: | https://journals.aboutscience.eu/index.php/grhta/article/view/3167 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|